Navigation Links
Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia
Date:3/3/2009

MONTREAL, March 3 /PRNewswire/ -- Enobia Pharma, an emerging Canadian biotech company focused on developing novel therapeutics for serious bone disorders, today announced completion of target enrollment in its pilot clinical trial in infants suffering from a severe form of hypophosphatasia. Enobia is investigating Enzyme Replacement Therapy (ERT) with ENB-0040 for the treatment of this rare and often crippling genetic bone disorder for which there is no approved treatment.

ENB-002-08 is an open-label, six month study evaluating safety, efficacy and pharmacokinetics of subcutaneous ENB-0040 in hypophosphatasia infants with severe rickets and respiratory compromise. Six severely affected infants from the EU, US and the Middle East will be treated at approved sites in the US, Canada, UK and the United Arab Emirates. Key efficacy outcomes include improvement in rickets and clinical manifestations of the disease. Results from the trial will be presented at the Endocrine Society meeting in June.

A Phase I study, which evaluated safety, tolerability and pharmacokinetics of ENB-0040 in adults with hypophosphatasia was completed in December of 2008. Results of that study will be presented at the American College of Medical Genetics in March.

"Everyone involved in the clinical program is extremely pleased with our progress," said Robert Heft, CEO of Enobia. "Since filing an IND only eight months ago, we have completed a Phase I study and enrolled this Phase I/II study in infants. We believe ENB-0040 will be shown to significantly improve the devastating skeletal manifestations of hypophosphatasia and may potentially be life-saving therapy for those suffering from the lethal form of the disease."

Additional trials are planned. If interested in learning more, contact '/>"/>

SOURCE Enobia Pharma Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Enobia Pharma Raises $40.1 Million Series B Financing
2. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
3. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
4. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
5. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
6. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Carrington Completes $8 Million Financing
9. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
10. New Brunswick Scientific Completes Merger Transaction with Eppendorf
11. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Dr. Greg Leyer ... 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics in ... is an annual continuing education conference for health care professionals. ... included the topic of probiotics in health. Dr. Leyer spoke ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015  El ... abre hoy su llamada a nominaciones para 2015. Este ... ha hecho, o tiene el potencial para hacer, contribuciones ... nominaciones se aceptarán hasta el 15 de marzo de ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... This release from ... -- or even whether -- invasive saltcedar should be controlled. The Society contends that ... and carefully weigh the impact of our decisions. , ... Lawrence, KS (PRWEB) August 24, 2009 -- Saltcedar (Tamarix spp.) is ...
... LEIDEN, The Netherlands and SEATTLE, August ... innovative products for hemostasis and,regenerative medicine, today announced the ... The financing round was led by new investor,Gilde Healthcare ... investor Index Ventures. Dirk Kersten from Gilde will join ...
... , SEATTLE, Aug. 21 Cell ... closing of its previously announced sale of $30 million of shares ... of its common stock in a registered offering to a single ... its shares of Series 2 Preferred Stock and to receive the ...
Cached Biology Technology:Invasive Saltcedar Triggers Lively Debate among Weed Scientists and Land Managers 2Invasive Saltcedar Triggers Lively Debate among Weed Scientists and Land Managers 3ProFibrix Raises US $11 Million (EUR 8 million) in Series B Financing 2ProFibrix Raises US $11 Million (EUR 8 million) in Series B Financing 3Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants 2
(Date:1/22/2015)... Jan. 22, 2015   EyeLock, Inc. , a market leader ... Steve Gerber to the new role of Senior ... for leading development of mobile platforms and wearable solutions for ... and innovation in the semiconductor industry to his role at ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 This ... media watermarking and fingerprinting markets. Watermarking aims to ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2
... BioScience includes the following peer-reviewed articles: Molecular ... Patrick J. Tranel and David P. Horvath. , Modern ... development of herbicide-resistant crops and a better understanding of ... of tools, including genomics, could yield novel and still ...
... system response that is critical to the first stages ... an entirely different direction than most scientists had thought, ... University Medical Center. "This finding will have ... development," said Michael Gunn, M.D., an immunologist and cardiologist ...
... Christopher Fasano (Memorial Sloan-Kettering Cancer Center) and colleagues lend ... stem cells outside of the neurogenic niche. , ... Bmi-1, maintains forebrain neural stem cell self-renewal. Overexpression of ... increases stem cell self-renewal both in vitro and in ...
Cached Biology News:BioScience tip sheet, March 2009 2New origin found for a critical immune response 2
... One can operate as a Voltage Clamp, as ... Clamp in electrophysiology research applications. Performance in any ... equipment. • This amazing ... in the capabilities of Digital Signal Processing (DSP) ...
... an enhanced ChemStation for the ... 2000 and Windows XP operating ... all new 7500 ICP-MS instruments ... new ChemStation using Microsofts Windows ...
... Microarrays designed for genome-wide microRNA expression ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive microRNA Expression ... The Soil Nematode microRNA Microarray ...
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Biology Products: